Clinical Trials Directory

We are doing this study to evaluate an experimental vaccine that is being developed to protect against C. diff infections. We want to find out if the study vaccine is effective for people who are at an increased risk for C. diff. We will look at how well the study vaccine can prevent infections and/or lower the severity of infections.

We are doing this study to find out if an experimental drug called navtemadlin (the study drug) is a safe and effective option for people with myelofibrosis (MF). We want to know how well it works when it is combined with ruxolitinib for people who did not get the desired results from ruxolitinib on its own.

People in this study will be placed into one of three groups. They will receive either L19IL2, L19TNF, or both L19IL2 and L19TNF. These treatments are given once a week for up to 4 weeks, or until the person’s tumors are gone.

L19IL2/L19TNF

We are doing this study to find the most effective, safe dose of an experimental drug called CLN-049 (the study drug) for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

We are doing this study to find out if the experimental combination and use of the drugs nivolumab and relatlimab can provide a benefit for people who are newly diagnosed with isocitrate dehydrogenase (IDH) wildtype glioblastoma (ndGBM).

We are doing this study to find out if continued use of an experimental drug called bomedemstat (the study drug) can provide an extended benefit for people with myeloproliferative neoplasms. We are enrolling people who have been in a previous study using the study drug and received a positive benefit.